UnitedHealth (UNH) Stock Soars 8% Following Medicare Advantage Rate Increase — Can It Last?

Key Takeaways

• UNH shares gained 8.16% in the past week, featuring a near-10% single-session jump
• CMS approved a 2.48% Medicare Advantage payment rate boost for 2027
• Bernstein lifted its price target to $411 while maintaining a Buy recommendation
• HSBC moved UNH to Hold; Baird’s Michael Ha stands as the only analyst with a Sell rating
• The stock remains down approximately 7% in 2025 and over 50% from its 2024 high

UnitedHealth Group (UNH) experienced its strongest weekly performance in seven months, surging more than 8% following an unexpected Medicare Advantage reimbursement rate increase from federal regulators.

UnitedHealth Group Incorporated, UNH

The Centers for Medicare & Medicaid Services confirmed a 2.48% boost to 2027 Medicare Advantage payment rates. This represented a significant upgrade from the agency’s initial proposal, which had projected rates would remain essentially unchanged.

The regulatory announcement triggered a substantial single-day rally approaching double digits. Market participants had anticipated a less favorable outcome, making the enhanced rate a welcome surprise.

For more than ten years, Medicare Advantage has served as a critical growth driver for UNH. However, escalating healthcare expenses combined with constrained federal reimbursements had begun compressing profit margins, making this decision particularly significant.

Bernstein responded swiftly to the development. The research firm increased its UNH price objective to $411 while reaffirming its Buy stance.

Bernstein’s analysis indicated the CMS ruling transforms what might have been approximately a 4% drag on 2027 profits into projected earnings expansion of about 1.4%. That represents a considerable shift in the financial outlook.

HSBC analyst Sidharth Sahoo elevated UNH to Hold on the announcement day. While not a strong buy signal, the upgrade reflects an improved risk-reward balance.

A Lone Dissenting Voice

The bullish sentiment isn’t universal. Baird’s Michael Ha maintained his Underperform stance, positioning himself as the sole analyst with a sell-equivalent recommendation among 31 firms tracking the company.

Ha contends the payment bump might only provide temporary relief. He pointed to persistent structural challenges facing value-based care frameworks that remain unresolved.

This perspective deserves consideration. The Medicare Advantage segment continues operating in a challenging landscape, despite the improved reimbursement environment.

Broader Context

UNH recently forecasted declining 2026 revenue — potentially marking its first yearly contraction in more than 30 years. Membership is projected to decrease across commercial insurance, Medicare, and Medicaid segments.

Shares remain down roughly 7% year-to-date and trade more than 50% beneath the 2024 peak. This week’s advance reduces those losses somewhat, but substantial distance remains to recovery.

Nevertheless, the analyst community leans positive overall. Among 31 firms covering UNH, 22 maintain Buy recommendations. The consensus 12-month price target suggests approximately 17% upside potential from present levels.

Optum, UNH’s healthcare services division encompassing pharmacy benefit management and direct care delivery, continues delivering earnings consistency while the traditional insurance operation faces challenges.

Market watchers are now focused on Q1 2026 results. Medical expense patterns and any revised Medicare Advantage profitability outlook will be critical focal points.

The post UnitedHealth (UNH) Stock Soars 8% Following Medicare Advantage Rate Increase — Can It Last? appeared first on Blockonomi.